Zealand Pharma A/S (ZEAL.CO)

653.00 +42.50 (+6.96%) 市場開市。 截至 03:04PM CEST。

Zealand Pharma A/S

Sydmarken 11
Søborg 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 270

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Adam Sinding Steensberg M.D.	President & CEO	11.89M	無	1974
Ms. Henriette Wennicke	EVP & CFO	4.85M	無	1983
Mr. Ivan Mourits Moller	Executive VP & COO	無	無	1972
Dr. David M. Kendall M.D.	Chief Medical Officer and Head of R&D	無	無	1961
Mr. Mads Kronborg	Head of Investor Relations & Communication	無	無	無
Mr. Ravinder Singh Chahil	EVP & General Counsel	無	無	1968
Ms. Christina Sonnenborg Bredal	Executive VP & Chief People Officer	無	無	1985
Dr. Jens Damsgaard Mikkelsen M.D.	Head of Molecular Pharmacology	無	無	無
Dr. Danilo Verge	Head of Global Medical Affairs	無	無	無
Lykke Romer	VP & Head of Finance and Accounting	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 DKK。

描述

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

公司管治

截至 2024年6月1日 止，Zealand Pharma A/S 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：5；董事會：1；股東權利：1；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。